Lymphoma

The National Comprehensive Cancer Network now recommends prophylactic monoclonal antibodies for immunosuppressed individuals, such as certain patients with cancer.

A phase 2 trial was recently launched to examine the safety and efficacy of oral inhibitor VK-2019 in patients with advanced Epstein-Barr Virus-positive nasopharyngeal carcinoma, a rare type of head and neck cancer, and lymphoma.

2021 was full of research advancements and FDA drug approvals that continue to improve cancer care for patients with a variety of malignancies.

New findings show that 43% of patients with certain blood cancers produced COVID-19 antibodies after receiving a third full dose of the mRNA vaccine.

The Food and Drug Administration approved Orencia, which is commonly used to treat conditions like rheumatoid arthritis, to prevent acute graft-versus-host-disease in adults and children who underwent a hematopoietic stem cell transplant from an unrelated donor.

The addition of a drug commonly used to treat arthritis may reduce the risk of graft-versus-host-disease in patients who underwent haploidentical allogeneic stem cell transplant.

The use of a novel drug combination yielded positive outcomes in patients with B-cell lymphomas for whom CAR-T cell therapy or stem cell transplant isn’t an option.

Researchers found that depression and anxiety may skew patient perceptions of participating in blood cancer clinical trials, thus contributing to low enrollment throughout the United States.

Patients with large B-cell lymphoma tended to have better quality of life that continued to improve over time after receiving Breyzani compared to those given standard of care.

The FDA approval of Rituxan plus chemotherapy is indicated for the treatment of children aged six months to 18 years who have various forms of lymphoma or a form of leukemia.

Patients aged 60 years and older with B-cell malignancies and those who were current or former smokers may have an increased risk for death after a COVID-19 infection, also outcomes may be better for those diagnosed after June 2020.

From Dick Vitale’s return to sportscasting after a brief pause for cancer treatment to a cancer survivor walking 3,000 miles cross-country, here’s what’s happening in the cancer landscape this week.

Although the interest of at-home care including the administration of cancer infusions has grown since the start of the COVID-19 pandemic, hesitation looms over its convenience, cost and safety.

A phase 1 trial of ONO-4685 was initiated for the evaluation of the antibody in patients with relapsed or refractory t-cell lymphoma.

The FDA’s recommendations are aimed at helping individuals and patients with breast cancer make better informed decisions about the decision to receive breast implants, according to experts.

Memory, attention and the ability to multitask may be affected in patients with lymphoma during and after chemotherapy treatment, which can impact one’s capability to complete daily tasks.

New research in blood cancer includes new treatment options for acute myeloid leukemia and a novel therapy using BK virus-specific T cells to treat BK virus-associated hemorrhagic cystitis.

“When survival became my identity, things began to shift in my life forever,” writes a blood cancer survivor.

A new T-cell therapy can be highly effective in treating BKV-associated hemorrhagic cystitis while minimizing side effects.

The ESPN sportscaster Dick Vitale was diagnosed with lymphoma, after receiving a melanoma diagnosis earlier this year.

Engineered cell technology is an example of ingenuity that brings together cutting-edge laboratory science and clinical trials to address aggressive cancers.

Patients with blood cancers may respond differently to doses of the COVID-19 vaccines based on the treatment they’re receiving, for example.

Natural killer cell therapy is making strides in blood cancer research, but there’s still much more to learn.

Caregivers of patients with cancer may face financial toxicity and stress — with little time to take care of themselves.

From Blink-182 bandmember Mark Hoppus’s cancer update to Olympian Elizabeth Beisel’s swim for cancer, here’s what’s happening in the cancer landscape this week.

While the recent FDA approval of Jakafi offers another effective option for patients with chronic GVHD, one expert urges that more work needs to be done to prevent and/or reverse the condition.

Certain races/ethnicities and ages may have worse outcomes in Hodgkin lymphoma regardless of variation in upfront chemotherapy.

The tome also reflects on his own diagnosis of cancer and how it influenced his practice.

The FDA has granted approval to Jakafi (ruxolitinib) for the treatment of chronic graft-versus-host disease (GVHD).

Patients with blood cancer who underwent stem cell transplant and developed chronic graft-versus-host disease have more treatment options than ever before. But the formula for planning older and newer therapies has not yet been established.